Drug Pipeline News

FDA grants Priority Review to Dupixent® for kids 6 months to 5 years

February 10, 2022

The US Food and Drug Administration has given Priority Review to the supplemental Biologics License Application for the use of Dupixent® as an add-on maintenance treatment for moderate-to-severe dermatitis in children aged 6 months to 5 years.